



New Claims (Attorney Docket No. LeA 36 288)

7. (New) The method as claimed in claim 3, where the selective PDE9A inhibitor is a compound of the formula




and the salts, solvates and solvates of the salts thereof.

8. (New) The method as claimed in claim 4, where the selective PDE9A inhibitor is a compound of the formula




and the salts, solvates and solvates of the salts thereof.

9. (New) The method as claimed in claim 5, where the selective PDE9A inhibitor is a compound of the formula



(I)

or



(II)


and the salts, solvates and solvates of the salts thereof.

Amended Claims (Attorney Docket No. LeA 36 288)

---


1. (Currently amended) ~~The use of selective PDE9A inhibitors for producing medicaments~~ A method for improving perception, concentration, cognitive processes, learning and/or memory comprising administering to a human or animal an effective amount of a selective PDE9A inhibitor.
2. (Currently amended) The ~~use~~ method as claimed in claim 1 for the prophylaxis and/or treatment of impairments of perception, concentration, cognitive processes, learning and/or memory.
3. (Currently amended) The ~~use~~ method as claimed in claim 2, where the impairment is a consequence of a disorder selected from the group consisting of dementia, stroke, craniocerebral trauma, Alzheimer's disease, Parkinson's disease, depression, or dementia with degeneration of the frontal lobes.
4. (Currently amended) ~~The use of PDE9A inhibitors for producing medicaments~~ A method for the treatment and/or prophylaxis of diseases of the central nervous system which are amenable to therapy through influencing the cGMP levels comprising administering to a human or animal an effective amount of a PDE9A inhibitor.
5. (Currently amended) The ~~use~~ method as claimed in claim 4, where the disease is selected from a group of diseases consisting of dementia, stroke, craniocerebral trauma, Alzheimer's disease, dementia with degeneration of the frontal lobes, Lewy body dementia, vascular dementia, attention deficit syndrome, impairments of attention and concentration, Parkinson's disease, schizophrenia, depression, affective disorders, psychoses, neuroses, anxiety, mania or manic depressive disorders, Pick's disease, pain and epilepsy.

6. (Currently amended) The ~~use~~ method as claimed in ~~any of claims~~ claim 1 to 5, where the selective PDE9A inhibitor is a compound of the formula



(I)

or



(II)

and the salts, solvates and solvates of the salts thereof.